Guerbet looks for 10% growth in 1995
This article was originally published in Clinica
Profits at French contrast media manufacturer Guerbet were up 9.2% to Fr 56 million ($11.4 million) in 1994 compared with 1993. Group turnover for the year was Fr 936.8 million, a rise of 3%, while R&D spending, which represented some 11% of revenues, totalled Fr 109 million. The company is expecting more rapid growth in 1995 than last year with larger profits in spite of product launches, says board president Dr Michel Guerbet in the company's annual report.
You may also be interested in...
The run-away US FDA advisory committee review of Biogen’s Alzheimer’s candidate was highly unusual. But like most things at the agency, not entirely unprecedented.
Trump Administration’s attempt to eliminate rebates in the US Medicare outpatient drug benefit program is the easiest and most certain item among the 11th hour pricing policy changes for the incoming Biden Administration to undo. But it still had a major impact on the dynamics of the drug pricing debate.
US FDA will simultaneously review the vaccines, with Moderna’s advisory committee set a week after Pfizer’s. ACIP emergency meeting scheduled for 1 December with vote likely on distribution priority for health care personnel.